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The long pentraxin 3 (PTX3) exerts a variety of regulatory functions in acute and chronic
tissue inflammation. In particular, PTX3 acts as an opsonin for a variety of pathogens
and endogenous particles. We hypothesized that PTX3 would exhibit opsonin-like
functions toward calcium oxalate crystals, too, and inhibit crystal growth. This process is
fundamental in kidney stone disease as well as in hyperoxaluria-related nephrocalcinosis,
the paradigmatic cause of chronic kidney disease (CKD) in children with primary
hyperoxaluria type I due to genetic defects in oxalate metabolism. Direct effects of PTX3
on calcium oxalate crystals were investigated in chemico by adding recombinant PTX3
to supersaturated calcium and oxalate solutions. PTX3, but not isomolar concentrations
of albumin, dose-dependently inhibited crystal growth. In vivo, the PTX3 protein was
undetectable in tubular epithelial cells and urine of wild-type mice under physiological
conditions. However, its levels increased within 3 weeks of feeding an oxalate-rich
diet, an exposure inducing hyperoxaluria-related nephrocalcinosis and CKD in selected
mouse strains (male and female C57BL/6N and male Balb/c mice) but not in others
(male and female 129SV and CD-1, male and female Balb/c mice). Genetic ablation
of ptx3 in nephrocalcinosis un-susceptible B6;129 mice was sufficient to raise the
oxalate nephropathy phenotype observed in susceptible strains. We conclude that PTX3
is an endogenous inhibitor of calcium oxalate crystal growth. This mechanism limits
hyperoxaluria-related nephrocalcinosis, e.g., in primary or secondary hyperoxaluria, and
potentially also in the more prevalent kidney stone disease.
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INTRODUCTION
Pentraxins are immunoregulatory acute phase proteins induced
upon disruption of homeostasis (1). The short pentraxins,
C-reactive protein and serum amyloid P are synthesized
in hepatocytes in response to IL-6. C-reactive protein and
serum amyloid P act as opsonins binding to a number of
microorganisms, dead cells, and other particles to facilitate
complement–mediated killing or phagocytosis (2). As opposed
to the short pentraxins, the long pentraxin PTX3 is locally
produced and released at sides of infection and inflammation by
several immune and non-immune cells, including neutrophils,
macrophages, myeloid dendritic, endothelial and epithelial cells
in response to inflammatory cytokines (i.e., IL-1β and TNF-α)
and Toll-like receptor agonists (3, 4). Importantly, expression of
PTX3 has been documented in the murine uroepithelium during
uropathogenic E. coli (UPEC) infections, where it enhances
phagocytosis of UPEC by innate immune cells (5). Indeed,
amongst the numerous immunoregulatory functions of this
pentraxin, recognition of extracellular particles (i.e., microbial
moieties) and promotion of their phagocytosis by macrophages,
neutrophils and dendritic cells are fundamental opsonic activities
(6–10).
Some extracellular particles are of crystalline nature and
account for a broad spectrum of acute and chronic diseases (11).
Numerous studies show that the cellular arm of the immune
system handles crystalline and non-crystalline extracellular
particles in a similar way, however little is known regarding
the role of humoral immune elements in the recognition and
control of crystalline particles (12–14). Here we focus on the
interaction of PTX3 with calcium oxalate (CaOx) crystals. CaOx
stones account for the vast majority of calculi in kidney stone
disease, i.e., nephro- and urolithiasis, affecting around 12% of
men and 5% of women during their lifetime (15). In addition,
intrarenal CaOx crystal retention causes nephrocalcinosis, a state
that is usually asymptomatic but can lead to progressive nephron
loss and chronic kidney disease (CKD), especially in rare genetic
forms of hyperoxaluria (15, 16). The traditional pathogenic
concept of nephrolithiasis and nephrocalcinosis is based on
urine supersaturation of minerals or on the lack of sufficient
crystallization inhibitors (17–19). Intratubular microcrystals
adhere to the luminal membrane of tubular epithelial cells via
a group of adhesion molecules (20–28). Adherent microcrystals
grow by apposition of minerals and ultimately form crystal plugs
obstructing tubules followed by nephron atrophy, interstitial
inflammation and fibrosis with loss of renal excretory function,
i.e., CKD (16, 29, 30).
Serum proteins, such as albumin as well as plasma fractions
containing alpha-globulins and beta-globulins inhibit CaOx
crystal aggregation via a variety of mechanisms (31, 32). We
recently observed that also the humoral immune effector and
opsonin immunoglobulin G inhibits CaOx crystal growth in vitro
(33). Because of their high molecular weight neither albumin nor
IgG pass the filtration barrier and are therefore not constituents
of the glomerular ultrafiltrate or urine in healthy individuals
and stone formers. We therefore hypothesized that an opsonin,
such as PTX3, which is likely expressed by tubular epithelial cells
(i.e., beyond the renal filtration barrier) and, therefore, directly
released into the urine (5), may act as an endogenous inhibitor
of CaOx crystal aggregation inside renal tubules. Thereby PTX3
might limit nephrocalcinosis during hyperoxaluria, a hypothesis
that is supported by the evidence presented and discussed in this
study.
RESULTS
Recombinant Human PTX3 Inhibits
Supersaturation-Induced CaOx Crystal
Aggregation
To test our hypothesis, we first added increasing doses
of recombinant human PTX3 or equimolar concentrations of
bovine serum albumin (BSA) to a supersaturated solution of
sodium oxalate and calcium chloride. The crystal preparation
was optimized to produce calcium oxalate monohydrate crystals,
since this species is mostly found in human oxalate kidney
stones (34, 35). Calcium oxalate monohydrate crystal formation
was confirmed by phase contrast microscopy and the crystal
size was assessed by digital morphometry 24 h later. PTX3, but
not bovine serum albumin, dose-dependently reduced crystal
size statistically significantly from a concentration of 100 nM or
higher (Figures 1A,B). The effect of rhPTX3 on calcium oxalate
crystal size distribution and, for comparison, that of equimolar
concentrations of BSA were confirmed by flow cytometry
based on intensity of the forward scatter signal from CaOx
monohydrate crystals (Figures 1C,D). Noteworthy, the reported
inhibitory effects of human albumin on kidney stone formation
rely on a different mechanism, which favors generation of di-
and trihydrate forms of calcium oxalate crystals (36). Both types
of crystals adhere poorly to the luminal membrane of tubular
epithelial cells and are flushed out more easily (25). Hence we
conclude that the long pentraxin PTX3 inhibits aggregation and
growth of CaOx monohydrate crystals in vitro at nanomolar
concentrations in a dose-dependent manner.
Hyperoxaluria-Induced Nephrocalcinosis Is
Associated With Tubular PTX3 Secretion
The human PTX3 is a 381 amino acid glycoprotein with
a predicted molecular weight of 40.165 Da. However, the
recombinant protein runs in SDS-PAGE gels at an apparent
MW of ∼45 kDa, due to N-linked glycosylation at Asn220
(37, 38). The functional PTX3 molecule is an homo-oligomer
that comprises eight identical protomer subunits (i.e., octamer)
with a total MW of ∼340 kDa (39, 40), which would most
likely prevent circulating PTX3 from passing the glomerular
filtration barrier and reaching the urine (40). PTX3 is expressed
by the murine uroepithelium during UPEC infections, and has
been described in the bladder of patients with urinary tract
infections (UTIs) (5), however expression of this pentraxin
in the human uroepithelium has not been documented yet.
Therefore, before assessing the role of PTX3 on CaOx crystal
growth in vivo, we first examined whether renal epithelial cells
express PTX3 and excrete it into the urine. The human protein
atlas (41, 42) reports no baseline expression of PTX3 mRNA in
four human renal epithelial cell lines (HEK293, NTERA-2, PC-3,
RPTEC-TERT1, data available at https://www.proteinatlas.org/
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FIGURE 1 | Recombinant human PTX3 inhibits supersaturation-induced CaOx crystal aggregation. (A) Calcium oxalate crystals were generated in chemico in the
presence of increasing concentrations of rhPTX3 and crystal size was measured microscopically 24 h later. (B) The effect of 1µM rhPTX3 on microscopically
measured calcium oxalate crystal size was compared to equimolar bovine serum albumin (BSA) and PBS. (C,D) Calcium oxalate crystals generated in the presence of
1µM BSA or equimolar rhPTX3 were compared for their forward scatter (FSC) signal intensity by flow cytometry and displayed for (C) relative frequency of FSC and
(D) overall FSC intensity. Data are from three independent experiments and represent means ± SEM in (A). n.s., not significant; *p < 0.05, ***p < 0.001 between
groups as indicated.
ENSG00000163661-PTX3/cell), no epithelial PTX3 positivity
using immunohistochemistry in healthy kidney samples
from three different donors (data available at https://www.
proteinatlas.org/ENSG00000163661-PTX3/tissue/kidney#imid_
18912581) and reports negative staining results in 12 renal cell
carcinoma samples (data available at https://www.proteinatlas.
org/ENSG00000163661-PTX3/ pathology). Consistent with this
scenario in humans and previous findings inmice (5), no staining
was observed for PTX3 in the kidney of normal mice. However, a
remarkable induction of tubular PTX3 expression was apparent
upon feeding mice an oxalate-rich diet (Figure 2A). Specificity
of the immunostaining was validated using an identical staining
protocol on renal sections of Ptx3-deficient mice (Figure 2A).
Consistent with these findings, western blot analyses of urine
samples from healthy mice on normal chow diet could not
detect the PTX3 protein, whereas those performed on mice
with diet-induced hyperoxaluria clearly showed it in the urine
(Figure 2B). Thus, renal tubular cells have the capacity to express
PTX3 and secrete it into the urine, e.g., during hyperoxaluria.
Lack of PTX3 Induces
Hyperoxaluria-Induced Nephrocalcinosis in
Non-susceptible B6;129SV Mice
Having shown that PTX3 is present in the urine during
hyperoxaluria, we sought to design an experiment that could
examine its putative role as an inhibitor of CaOx crystallization.
We selected the B6;129-Ptx3tm1Mant mice that has global PTX3-
deficiency to unravel the role of this pentraxin in CaOx crystal
aggregation-related disease, i.e., in amodel resembling the kidney
phenotype of primary hyperoxaluria type I or other forms of
progressive nephrocalcinosis. Ptx3−/− or Ptx3+/+ littermates
from heterozygous breeders were fed with a sodium oxalate-rich
diet for 3 weeks. Despite the equal induction of hyperoxaluria
in both genotypes (Figure 3A), only the Ptx3-deficient mice
developed a nephrocalcinosis (Figures 3B,C). X-ray diffraction
on pulverized and freeze dried murine Ptx3−/− kidney tissue,
that were fed for 3 weeks with oxalate chow, confirmed the
presence of calcium oxalate monohydrate crystals in the kidneys,
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FIGURE 2 | Hyperoxaluria-induced nephrocalcinosis is associated with tubular PTX3 secretion. Female PTX3-competent (Ptx3+/+) and -deficient (Ptx3−/−) animals
with 10–12 weeks of age received either control or oxalate chow for 3 weeks (n = 5). (A) Tubular expression of PTX3 was analyzed by immunohistochemical staining
in frozen kidney sections and quantified as positive stained area per section in percent. (B) Detection of PTX3 in whole urine samples by immunoblotting (25 µg
protein/lane, upper right). Ponceau Red staining shows major urinary proteins (mainly a2u-globulins, ∼20 kDa, lower right) as a loading control. Optical density of the
immunoreactive and Ponceau Red stained bands was quantified by ImageJ (NIH, Bethesda, MD). Data are from two independent experiments. n.s., not significant;
*p < 0.05, ***p < 0.001 between groups as indicated.
as judged based on the diffraction angle pattern (Figure 3D).
Therefore, the B6;129 mice were not susceptible per se to
hyperoxaluria-induced nephrocalcinosis, however deletion of the
ptx3 gene was sufficient to induce nephrocalcinosis in these
animals, thus rendering them similar to other strains that are
prone to nephrocalcinosis (43).
Lack of PTX3 Induces
Hyperoxaluria-Induced Progressive CKD in
Non-susceptible B6;129 Mice
A detailed phenotype analysis revealed profound and progressive
nephrocalcinosis-related tubular injury in Periodic acid-Schiff
(PAS)-stained kidney sections (Figures 4A,B) with CaOx crystal
plugs (Figure 4C) in dilated tubules in Ptx3−/− but not
in Ptx3+/+ B6;129 mice. Tissue remodeling was further
obvious from diffuse cortical and medullary interstitial fibrosis
as indicated by interstitial positivity for smooth muscle
actin (Figures 4D,E). Diffuse interstitial leukocyte infiltrates as
assessed by flow cytometry from whole kidney homogenates
(Figure 4F) indicated ongoing inflammatory processes. Finally,
renal excretory function was assessed by measuring glomerular
filtration rate (GFR) in awake and unrestrained mice using
FITC-sinistrin injection and quantifying vascular FITC clearance
kinetics with a transdermal detector (Figure 4G). Ptx3−/− and
Ptx3+/+ mice showed identical GFR before onset of oxalate diet
feeding. While GFR remained constant in Ptx3+/+ mice over
the entire feeding period, Ptx3−/− mice showed a linear decline
of GFR as previously reported for susceptible mouse strains
(43). Thus, Ptx3-deficient mice display the full phenotype of
hyperoxaluria-induced nephrocalcinosis and progressive CKD.
Together with the in vitro data described above, we conclude that
PTX3 is an endogenous inhibitor of CaOx crystal aggregation,
nephrocalcinosis and CKD during hyperoxaluria.
PTX3 Abolishes Crystal Adhesion Molecule
Expression in vitro and in vivo
Based on the data gathered from our in vitro and in vivo
experiments so far, we assumed that PTX3 opsonizes small
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FIGURE 3 | Lack of PTX3 induces hyperoxaluria-induced nephrocalcinosis in non-susceptible B6;129SV mice. Female PTX3-competent (Ptx3+/+) and -deficient
(Ptx3−/−) animals with 10–12 weeks of age received oxalate chow for 3 weeks (n = 9). (A) Oxalic acid levels in urine at baseline and after 3 weeks of oxalate chow.
(B) Quantification of calcium oxalate crystal deposition was conducted using Pizzolato’s method on formalin fixed kidney sections as shown in (C). (D) Analysis of
PTX3−/− kidneys by X-ray diffraction consistent with calcium-oxalate monohydrate crystals. Data are from four independent experiments. n.s., not significant;
*p < 0.05, ** p< 0.01 vs. wild type and respective #, ##, and ### vs. week 1 as indicated.
CaOx crystals and thereby inhibits further crystal growth
and aggregation, which would result in vivo in crystal plug
formation, kidney injury and progressive CKD. Nevertheless,
nephrocalcinosis does not solely depend on the crystal
aggregation, but also on the adhesion of crystals to the luminal
side of tubular cells, a process that is enabled by crystal adhesion
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FIGURE 4 | Lack of PTX3 induces hyperoxaluria-induced progressive CKD in non-susceptible B6;129 mice. Ptx3+/+ and Ptx3−/− female littermates (10–12 weeks
of age) were fed with oxalate chow for 3 weeks (n = 9). (A) Quantification of tubular injury was conducted using PAS-stained kidney sections as shown in (B). (C)
Phase contrast image of crystal plugs in H&E-stained kidney section in 200× (left) and 400× (right) magnification. (D) Quantification of αSMA-positive area in kidney
sections after 3 weeks of either control or oxalate chow feeding as shown in (E). (F) Percentage of CD45+ cells within whole kidney cell suspension assessed by flow
cytometry. (G) GFR assessed by transcutaneous measurement of FITC-sinistrin from subcutaneous capillaries at weeks 0, 1, 2, and 3 after onset of high oxalate diet
in both genotypes. Data are from four independent experiments and represent means ± SEM in (G). n.s., not significant; *p < 0.05, **p < 0.01, ***p < 0.001 vs. wild
type and respective #, ##, and ### vs. week 1 as indicated.
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molecules expressed on the cell surface, e.g., CD44 and annexin
II. To address this point in vitro, we isolated primary murine
proximal tubular cells from PTX3+/+ and PTX3−/− littermates
with 3 weeks of age and stimulated them with PBS or 500µg/ml
CaOx crystals (1–2µM size). After 24 h total RNA was isolated,
transcribed to cDNA and Cd44 and Anxa2 expression levels
were quantified by qPCR (Figures 5A,B). Expression of both
mRNAs was induced in tubular cells of PTX3-deficient mice
stimulated with crystals only, whereas PTX3-competent cells
did not upregulate the expression of either adhesion molecule.
Similarly, in vivo, after 3 weeks of control or oxalate chow
diet, the expression of CD44 and annexin II was upregulated
in tubular cells of Ptx3-deficient mice exposed to the oxalate
chow only (Figures 5C–F). From these findings we conclude,
that PTX3 not only inhibits CaOx crystal growth, but also
abolishes the upregulation of crystal adhesion molecules after
CaOx crystal challenge in vitro and in vivo, thereby additionally
counteracting the development of nephrocalcinosis and CKD
under hyperoxaluric conditions.
Development of Nephrocalcinosis and
CKD Under Hyperoxaluric Conditions Is
Strain and Sex Dependent
Our data from this and prior studies (43) suggest that the
model of hyperoxaluria-induced nephrocalcinosis might be
strain-dependent. To address this point, we compared the
phenotypes of hyperoxaluric and control male and female mice
on C57BL/6N, BALB/c, and CD-1 backgrounds, respectively.
Pizzolato’s staining method for CaOx crystals revealed, that
out-bred CD-1 mice were not susceptible to nephrocalcinosis
in our model (Figures 6A,B). In BALB/c mice, only males
displayed CaOx crystal deposition, whereas females were
protected. C57BL/6N mice of both sexes were susceptible
to hyperoxaluria-induced nephrocalcinosis. In line with the
presence of CaOx deposits in the kidneys, only BALB/c male
as well as male and female C57BL/6N animals displayed
tubular injury in PAS-stained sections, although the degree of
injury was less profound in BALB/c compared to C57BL/6N
(Figures 6C,D). Remarkably only hyperoxaluric C57BL/6N
animals showed signs of fibrotic tissue remodeling, as assessed by
collagen I-stained sections (Figures 6E,F), whereas BALB/c male
mice did not. Characterizing the excretory kidney function we
measured plasma levels of creatinine (Figure 6G), urea nitrogen
(Figure 6H) and phosphorus (Figure 6I). Hyperoxaluric
C57BL/6N mice of both sexes showed significantly increased
levels of all three markers, whereas hyperoxaluric BALB/c male
mice did not develop hyperphosphatemia and displayed lower
levels of plasma creatinine and BUN compared to C57BL/6N.
Based on this data we questioned whether the dependency of
crystal formation from sex and strain was associated with the
intrarenal levels of the PTX3 protein. Immunohistochemistry
revealed a downregulation of PTX3 in male and female
C57BL/6N mice fed with high oxalate diet compared to control
animals, a phenomenon partly observed in male BALB/c animals
also, although to a lesser extend (Supplementary Figures 1A,B).
Non-crystal-forming female BALB/c and CD-1 mice of both
sexes did not show PTX3 regulation. The animals with high
oxalate diet which showed crystal deposition in the kidney
were negative for PTX3, as shown using immunohistochemistry
(Supplementary Figures 1C,D) and Western blotting in urine
(Supplementary Figures 1E,F).
We conclude that genetic factors control susceptibility for
hyperoxaluria-related nephrocalcinosis and that PTX3 is an
endogenous inhibitory factor preventing nephrocalcinosis and its
deterious consequences, e.g., by limiting crystal growth and by
induction of crystal adhesion molecules.
DISCUSSION
We had speculated that the long pentraxin PTX3, an opsonin
known to interact with dead cells and other extracellular
microparticles, would affect CaOx crystal aggregation and
growth, central pathomechanisms in kidney stone disease
and nephrocalcinosis. Our data revealed that recombinant
PTX3 limits CaOx crystal aggregation in vitro. Furthermore,
during hyperoxaluria in vivo renal tubular cells secrete PTX3
which serves as an endogenous inhibitor of intrarenal crystal
aggregation and adhesion, nephrocalcinosis, kidney injury, and
subsequent CKD. Although not regulated in all investigated
strains and sexes in the same manner, PTX3 protein levels
associated with a lack of crystal formation in high oxalate
diet exposed animals, further supporting a functional role of
PTX3 as a calcium oxalate crystallization inhibitor. Our study
identified a novel role of the opsonin and immune regulator
PTX3 as a modulator of CaOx crystal aggregation and adhesion.
Our data showed that PTX3 is one of several endogenous
inhibitors of stone formation in nephrocalcinosis and potentially
in urolithiasis or other crystallopathies.
The PTX3 protomer subunit comprises an N-terminal region,
unrelated to any known protein structure, and a C-terminal
domain, homologous to the short pentraxins CRP and SAP.
In our study, we did not investigated which domain of the
PTX3 protein mediates the inhibitory functions described
above. This will be the subject of future investigations. In
this regard, it is worth noting that other proteins, that are
known to inhibit growth and aggregation of calcium oxalate
crystals, e.g., Tamm-Horsfall glycoprotein, a1-microglobulin or
prothrombin fragment 1 (44), do not share well-characterized
homologous amino acid sequences with PTX3. In the past
scientific approaches to identify proteins with function in stone
formation were usually conducted by characterizing protein
composition of urinary stones (45, 46). In doing so, the
possible contribution of carbohydrate side chains of proteins
was discussed (45). Subsequent research supported the notion
that protein-beared oligosaccharides could be involved in the
overall inhibitory effect of glycoproteins on crystal growth, e.g.,
sialic acid side chains on Tamm-Horsfall protein (47, 48). The
most efficient modifiers of calcium stones have a large number
of carboxylic, hydroxyl, sulfate or phosphate functions on their
structure (49). The PTX3 protein has a single N-glycosylation site
in the C-terminal domain that is occupied by fucosylated and
sialylated complex type sugars (37, 38). This post-translational
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FIGURE 5 | PTX3 abolishes crystal adhesion molecule expression in vitro and in vivo. (A,B) Primary murine proximal tubular cells were isolated from Ptx3+/+ and
Ptx3−/− littermate mice with 3 weeks of age and stimulated with PBS and 500µg/ml CaOx crystals, respectively (n = 4). Total RNA was isolated and transcribed to
cDNA. Subsequent qPCR for (A) Cd44 and (B) AnxaII expression was conducted. (C–F) Ptx3+/+ and Ptx3−/− female littermates (10–12 weeks of age) were fed with
oxalate chow for 3 weeks and formalin kidney sections were stained for (C,D) CD44 and (E,F) Annexin II, respectively (n = 5). n.s., not significant; *p < 0.05,
**p < 0.01, ***p < 0.001 vs. wild type and respective ## and ### vs. PBS as indicated.
modification has been documented to affect the binding of PTX3
to a number of ligands, including complement components
(37, 50) and P-selectin (51), thereby effectively altering the
immune-modulatory properties of PTX3. It is worth noting
here that throughout our study a recombinant preparation of
PTX3 from Per.C6 cells was used, which is N-linked glycosylated
(based on SDS-PAGE of the PNGase F-treated protein; data
not shown). However, we cannot rule out that the glycosidic
moiety of the Per.C6-derived proteinmight differ from that of the
CHO-expressed PTX3 (i.e., that was used in previous reports).
Although beyond the scopes of the study, this is an interesting
point that deserves further investigations. Nonetheless, based on
the body of literature available, it appears licit to speculate that
the glycosylation status of PTX3 (with major regard to fucose and
sialic acid-content) might influence the protein’s properties as an
inhibitor of crystal growth.
Another possible route of action for PTX3 that needs
further investigation, is related to its association with TNF-α
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FIGURE 6 | Development of nephrocalcinosis and CKD under hyperoxaluric conditions is strain and sex dependent. Male and female BALB/c, C57BL/6N, and CD-1
mice (8 weeks of age) were fed with control or oxalate chow for 3 weeks (n = 5). (A) Quantification of calcium oxalate crystal deposition was conducted using
Pizzolato’s method on formalin fixed kidney sections as shown in (B). (C) Quantification of tubular injury was conducted using PAS-stained formalin fixed kidney
sections as shown in (D). (E) Quantification of Collagen I deposition was conducted using Collagen I-stained formalin fixed kidney sections as shown in (F). (G)
Plasma creatinine, (H) blood urea nitrogen, and (I) plasma phosphorus were analyzed Cobas Integra 800 autoanalyzer. n.s., not significant; *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001 between treatment groups.
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signaling. We were previously able to show, that crystal
adhesion to the luminal membrane of renal tubules requires
TNFR signaling (28). The connection between TNF-α and
PTX3 is well-established and indicates that PTX3 expression
is a downstream event of TNF-α signaling (52), but also
that PTX3 itself can inhibit TNF-α induced transcription
factor activation (53). Hence, altered TNFR signaling might
be involved in the phenotype observed in Ptx3-deficient
mice.
Although technically feasible, we did not consider to recover
the wild type mouse nephropathy phenotype by reconstituting
the lack of PTX3 in Ptx3-deficient mice by injecting recombinant
PTX3 because the PTX3 protein octamer is too large to pass the
glomerular filter (40). Without a chance of reaching the tubular
lumen, exogenous administered PTX3 cannot exert protective
effects under hyperoxaluric conditions, which greatly limits its
potential usefulness as a therapeutic intervention.
Nevertheless, we identified PTX3 as a previously unknown
endogenous protein inhibitor of intrarenal CaOx crystal growth
and adhesion (49). The field agrees that nephrocalcinosis, kidney
stone disease and urolithiasis do not have a monogenic cause
(54). Rather an increasing list of candidate genes is assembled
by whole genome genotyping approaches using nephrolithiasis
patient cohorts (55, 56). Our data suggest to include Ptx3 in
the list of candidate genes, that might contribute to a better
understanding of stone diseases and prove useful in future patient
diagnosis and management. Additionally, the investigation of
different strains and sexes revealed, that decreased PTX3 protein
expression associates with stone formation in some animals
(C57BL/6N male and female), whereas other animals, that are
not susceptible for hyperoxaluria-induced nephrocalcinosis, did
either not show any PTX3 protein regulation (CD-1 male and
female) or upregulated PTX3 under hyperoxaluric conditions
(Ptx3-competent mice of the mixed B6;129 background). These
in vivo observations might serve as a hint for the clinical
setting, where haplotype compositions of each patient differ and
some stone formers might show differences in PTX3 protein
regulation, whereas others do not. PTX3 polymorphisms have
already been shown to greatly influence the susceptibility of
patients to aspergillosis, probably due to mRNA instability in
some SNPs (57). Our data provide the rational for a similar study
regarding kidney stone patients.
We reported the model of experimental hyperoxaluria-
induced nephrocalcinosis to be valuable and clinically relevant
for CKD research in male and female C57BL/6N mice (43).
Next, the absence of nephrocalcinosis in Ptx3+/+ animals on
B6;129 background 3 weeks after model induction prompted
us to study issues of strain and sex dependency in this model.
With both sex and background affecting CaOx deposition with
different degrees we believe that this model became even more
valuable for studying mechanisms and risk factors related to
kidney stone diseases. In silico comparison and transcriptome
analysis of different murine strains and sexes available are very
likely to draw a very precise picture on disease related genetic risk
factors and possible therapeutic targets.
For CKD research—apart from the unique pathomechanisms
only found in crystallopathies—strain and sex dependency of
the model point out that researchers need to apply great care
when using genetically-modified organisms, that were generated
from different backgrounds or not completely backcrossed.
Also, this does not only hold true for hyperoxaluria-induced
nephrocalcinosis, but for a variety of other renal inflammatory
models and conditions, e.g., thioglycolate-induced peritonitis
(58), inflammatory response and albuminuria in response to
albumin-overload (59), anti-GBM glumerulonephritis (60) as
well as response to nephrotoxins (61).
In summary, the opsonin and immune regulator PTX3 also
modulates CaOx crystal aggregation and adhesion to tubular
cell membranes and is therefore one of several endogenous
inhibitors of stone formation in nephrocalcinosis and potentially
in urolithiasis or other crystallopathies.
MATERIALS AND METHODS
Animal Studies
BALB/c, C57BL/6N, and CD-1 mice were purchased from
Charles River Laboratories (Sulzfeld, Germany). Ptx3-deficient
mice in the B6;129 background were obtained from Alberto
Mantovani/ Charles River Italy and were generated as previously
described (62). Mice were co-housed in groups of five in filter
top cages with unlimited access to food and water. Cages,
nestlets, food, and water were sterilized by autoclaving before use.
Eight-to-twelve-weeks-old male mice were used for experiments.
Oxalate diet was prepared by adding 50 µmol/g sodium oxalate
to a calcium-free standard diet (Ssniff, Soest, Germany) as
previously described (43, 63). Mice were sacrificed at day 7, 14,
and 21 after starting oxalate diet. Plasma and urine samples
were collected and GFR was measured at different time points
before cervical dislocation. Urine was immediately acidified for
oxalate estimations or centrifuged for 10min at 10,000 g for
cellular component removal and stored at −80◦C. One part of
each kidney was fixed in formalin and subsequently embedded
in paraffin for histological analysis. All experimental procedures
were approved by the local government authorities.
Assessment of Renal Injury
Kidney sections of 2µm were stained with periodic acid-Schiff
(PAS) reagent, and the tubular injury was scored by assessing
the percentage of necrotic tubules and presence of tubular
casts. Pizzolato’s staining was used to visualize CaOx crystals
and crystal deposit formation in the kidney was evaluated as
described (43). Fibrotic areas were identified by immunostaining
for αSMA (Dako GmbH, Germany) and collagen I (Abcam,
Cambridge, UK). The expression of crystal adhesion molecules
e.g., CD44 and Annexin II was identified by immunostaining
for CD44 and Annexin II (both Abcam, Cambridge, UK). PTX3
expression was identified in paraformaldehyde-fixated and cryo-
cut tissue samples using a polyclonal rabbit anti-human PTX3
antibody (Enzo Life Sciences, Farmingdale, USA).
Quantification of Pizzolato’s silver stain and immunostainings
was done using Image J software. All assessments were performed
by an observer blinded to the experimental condition. Plasma
BUN, creatinine and phosphorus levels were measured using a
Cobas Integra 800 autoanalyzer (Roche, Mannheim, Germany).
Frontiers in Immunology | www.frontiersin.org 10 September 2018 | Volume 9 | Article 2173
Marschner et al. Novel Crystallization Inhibitor PTX3
Assessing the signal intensity of the PTX3 staining in
C57BL/6N, BALB/c, and CD-1 animals was not feasible using
ImageJ, as big calcium oxalate crystal deposits were visible in
the cryosections, showing the same level of contrast as the
immunostaining. Hence, PTX3 staining was semi-quantitatively
assessed using a scoring system where a strong positive signal
was scored with a value of 2, a weak signal with a value of 1 and
absence of signal with a value of 0. This evaluation was conducted
independently for the cortex, medulla and papilla of one kidney
section and the overall score resulted from the sum of all values,
possibly raging of 0 to 6.
Transcutaneous Measurement of
Glomerular Filtration Rate (GFR) in
Conscious Mice
For GFR measurement mice were anesthetized with isoflurane
and a miniaturized imager device built from two light-emitting
diodes, a photodiode and a battery (MediBeacon, Mannheim,
Germany) was mounted via a double-sided adhesive tape onto
the shaved animals’ neck (64). For the duration of recording
(∼1.5 h) each animal was conscious and kept in a single cage.
Prior to the intravenous injection of 150 mg/kg FITC-sinistrin
(MediBeacon, Mannheim, Germany), the skin’s background
signal was recorded for 5min. After removing the imager device
the data were analyzed using MPD Lab software (MediBeacon,
Mannheim, Germany). The GFR [µl/min] was calculated from
the decrease of fluorescence intensity over time (i.e., plasma
half-life of FITC-sinistrin) using a two-compartment model, the
animals body weight and an empirical conversion factor (64).
X-ray Diffraction Analysis of Intrarenal
Crystals
The analysis of the freeze dryed mouse kidney tissue by X-
ray powder diffraction was performed with an Empyrean setup
from PANalytical. A Cu x-ray tube (line source of 12 × 0.04
mm2) provided CuKa radiation with l = 0.1542 nm. The Kb
line was removed by a Ni filter. Source and detector moved in
the vertical direction around a fixed horizontal sample. After
passing a divergence slit of 1/8◦ and an anti-scatter slit of 1/4◦,
the beam reached the sample at the center of a phi-chi-z stage. In
the Bragg-Bretano geometry used, the beam was refocused at a
secondary divergence slit of 1/4◦. Finally, the signal was recorded
by a pixel detector (256 × 256 pixels of 55µm) as a function of
the scattering angle 2θ . Subsequently, the peak positions were
calculated from q = 2pi/d = (4pi/λ) sinθ , in which q is the
scattering vector. The detector was used in a scanning geometry
that allowed all rows to be used simultaneously.
Flow Cytometry
Whole kidneys were chopped and digested for 30min at 37◦C
using a collagenase and DNase I solution (both Sigma-Aldrich,
Taufkirchen, Germany). Samples were further strained through
a 70µm mesh and washed with PBS. Dead cells were excluded
from analysis using the Zombie NIRTM Fixable Viability Kit
according to the manufacturer’s instructions and as described
TABLE 1 | Primer sequences for qPCR.
Target Primer sequence
CD44 Forward
Reverse
5′-AGCGGCAGGTTACATTCAAA-3′
5′-CAAGTTTTGGTGGCACACAG-3′
Annexin II Forward
Reverse
5′-GCACATTGCTGCGGTTTGTCAG-3′
5′-CACCAACTTCGATGCTGAGAGG-3′
18s RNA Forward
Reverse
5′-GCAATTATTCCCCATGAACG-3′
5′-AGGGCCTCACTAAACCATCC-3′
before (65). CD45+ positive cells were identified using a PE-
CyTM5 labeled antibody (clone 30-F11, BD Biosciences, Franklin
Lakes, USA). Analysis was conducted using FlowJo v10.0.
Cell Culture Studies
Primary tubular epithelial cells (pTECs) were isolated
from kidneys of mice with 3 weeks of age and were
maintained in DMEM/F12 containing 10% fetal calf serum,
1% penicillin–streptomycin, 125 ng/ml prostaglandin E1
(Calbiochem, Darmstadt, Germany), 25 ng/ml EGF, 1.8µg/ml
l-thyroxine, 3.38 ng/ml hydrocortisone and 2.5 mg/ml of
insulin-transferrin-sodium selenite supplement (I-T-SS)
(all from Sigma-Aldrich, Taufkirchen, Germany unless
mentioned) as previously described (66, 67). All cells were
cultured in an incubator at 37◦C, 5%CO2, and stimulated
with crystals of CaOx (1–2µm size; Alfa Aesar, Karlsruhe,
Germany).
RNA Preparation and Real-Time
Quantitative PCR
Total RNA was isolated from pTECs using a Qiagen
RNA extraction kit (Düsseldorf, Germany) following the
manufacturer’s instructions. After quantification RNA
quality was assessed using agarose gels. From isolated
RNA, cDNA was prepared using reverse transcriptase
(Superscript II; Invitrogen, Carlsbad, USA). Real-time
quantitative PCR (qPCR) was performed using SYBRGreen
PCR master mix and was analyzed with a Light Cycler
480 (Roche, Mannheim, Germany). All gene expression
values were normalized using 18S rRNA as a housekeeping
gene. All primers used for amplification were from
Metabion (Martinsried, Germany), and are listed in
Table 1.
Immunoblotting
After determination of protein concentrations in urine samples,
50 µg of the protein solution was mixed with 4× sodium
dodecyl sulfate loading buffer and was denatured at 95◦C for
5min for western blot analysis. Proteins were then separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to a polyvinylidene difluoride membrane. Non-
specific binding to the membrane was blocked for 1 h at room
temperature with 5% non-fat milk in tris-buffered saline. The
membranes were then incubated overnight at 4◦Cwith a primary
antibody for PTX3 (clone 2C3, Hycult Biotechs, Plymouth
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Meeting, USA) followed by incubation with a secondary rabbit
anti-mouse IgG HRP-labeled antibody. Immunostained bands
were detected using a chemiluminescence kit (ECL kit, GE
Healthcare, Cardiff, UK). Equal loading of urinary proteins was
visualized by Ponceau Red staining (1 h at RT). Stain intensities
for both stainings were further analyzed by densitometry (Image
J). Murine PTX3 from urine samples as well as the recombinant
PTX3 positive control showed the expected band around 45
kDa.
In Chemico Generation and
Characterization of Calcium Oxalate
Crystals
Calcium oxalate crystals of defined size and shape were
generated as described elsewhere (68). In short, 10mM
sodium oxalate and 1mM calcium chloride solutions
were prepared using a 10mM TRIS-HCl buffer (pH 7.3).
For CaOx crystal generation 1 volume sodium oxalate
solution was incubated over night at 4◦C with 0.5 volume
of either PBS or rhPTX3 in different concentrations.
Next, 1 volume calcium chloride solution was added and
kept at 4◦C for 24 h. CaOx crystal size in the different
preparations was assessed using bright light microscopy or flow
cytometry.
Recombinant Human PTX3
Human PTX3 was recombinantly expressed in a PerC6
human cell line. Briefly, Per.C6 cells (Crucell, Leiden, The
Netherlands) were stably transfected with a plasmid vector
(pcDNA2001Neo-hPTX3) carrying the human PTX3 cDNA
under control of the CMV promoter. After transfection,
a highly producing clone was selected and expanded for
protein expression. The recombinant protein was purified
from conditioned medium using a multi-step chromatography
strategy as previously described (69). Protein homogeneity
in the end-product was assessed by analytical size exclusion
chromatography (SEC), SDS-PAGE and immunoblotting (39).
N-linked glycosylation of the purified protein was investigated
using PNGase F (Sigma Aldrich) as previously described
(37).
Statistical Analysis
Data are presented as mean with SEM or as boxplot statistics.
Prior to every other statistical analysis, data were checked
for normal distribution (Shapiro-Wilk test), homoscedasticity
(Levene’s test) and outliers (Grubb’s test). Normally distributed
and homoscedastic data sets were tested for statistical significant
differences via ANOVA and post-hoc Bonferroni’s correction
was used for multiple comparisons. Heteroscedastic data were
corrected following Games-Howell’s post-hoc test. Not normally
distributed data sets were compared using Kruskal-Wallis and
Nemenyi testing. A value of p < 0.05 was considered to indicate
statistical significance. P-values were indicated as p > 0.05 n.s.,
p< 0.05 ∗ (or #), p< 0.01 ∗∗ (or ##), p< 0.001 ∗∗∗ (or ###).
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Supplementary Figure 1 | PTX3 protein expression under hyperoxaluric
conditions in different strains and sexes. Male and female BALB/c, C57BL/6N,
and CD-1 mice (8 weeks of age) were fed with control or oxalate chow for 3
weeks (n = 5). (A) Scoring PTX3 positivity was performed on PTX3
immunostained cryosections as shown in (B). Calcium oxalate crystal deposits are
indicated with asterisks. (C–F) The figures include only those animals from the
study, that were exposed to oxalate diet, not the control animals. (C) Comparing
PTX3 staining scores between animals developing crystal deposition and those
that did not, based on PTX3 immunohistochemistry on cryosections and
Pizzolato’s staining for oxalate crystals on paraffin sections (D). (E) Comparing
optical densities of immunoblots for PTX3 from urine samples (25 µg protein/lane)
analogous to (C,D). (F) Western blot for PTX3 (∼45 kDa, upper panel) and
Ponceau Red staining for major urinary proteins (mainly a2u-globulins, ∼20 kDa,
lower panel) as a loading control. Data are from one experiment. n.s., not
significant; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001 between groups as indicated.
Frontiers in Immunology | www.frontiersin.org 12 September 2018 | Volume 9 | Article 2173
Marschner et al. Novel Crystallization Inhibitor PTX3
REFERENCES
1. Erreni M, Manfredi AA, Garlanda C, Mantovani A, Rovere-Querini P.
The long pentraxin PTX3: a prototypical sensor of tissue injury and a
regulator of homeostasis. Immunol Rev. (2017) 280:112–25. doi: 10.1111/imr.
12570
2. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral
innate immunity: pentraxins as a paradigm. Annu Rev Immunol. (2010)
28:157–83. doi: 10.1146/annurev-immunol-030409-101305
3. Bottazzi B, Garlanda C, Salvatori G, Jeannin P, Manfredi A, Mantovani A.
Pentraxins as a key component of innate immunity. Curr Opin Immunol.
(2006) 18:10–5. doi: 10.1016/j.coi.2005.11.009
4. Nauta AJ, de Haij S, Bottazzi B,Mantovani A, BorriasMC, Aten J, et al. Human
renal epithelial cells produce the long pentraxin PTX3. Kidney Int. (2005)
67:543–53. doi: 10.1111/j.1523-1755.2005.67111.x
5. Jaillon S, Moalli F, Ragnarsdottir B, Bonavita E, Puthia M, Riva F, et al.
The humoral pattern recognition molecule PTX3 is a key component of
innate immunity against urinary tract infection. Immunity (2014) 40:621–32.
doi: 10.1016/j.immuni.2014.02.015
6. Diniz SN, Nomizo R, Cisalpino PS, Teixeira MM, Brown GD, Mantovani
A, et al. PTX3 function as an opsonin for the dectin-1-dependent
internalization of zymosan by macrophages. J Leukoc Biol. (2004) 75:649–56.
doi: 10.1189/jlb.0803371
7. Baruah P, Dumitriu IE, Peri G, Russo V, Mantovani A, Manfredi AA, et
al. The tissue pentraxin PTX3 limits C1q-mediated complement activation
and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol. (2006)
80:87–95. doi: 10.1189/jlb.0805445
8. Jaillon S, Jeannin P, Hamon Y, Frémaux I, Doni A, Bottazzi B, et al.
Endogenous PTX3 translocates at the membrane of late apoptotic human
neutrophils and is involved in their engulfment by macrophages. Cell Death
Differ. (2009) 16173:465–74. doi: 10.1038/cdd.2008.173
9. Rovere P, Peri G, Fazzini F, Bottazzi B, Doni A, Bondanza A, et
al. The long pentraxin PTX3 binds to apoptotic cells and regulates
their clearance by antigen-presenting dendritic cells. Blood (2000)
96:4300–6.
10. van Rossum AP, Fazzini F, Limburg PC, Manfredi AA, Rovere-Querini
P, Mantovani A, et al. The prototypic tissue pentraxin PTX3, in contrast
to the short pentraxin serum amyloid P, inhibits phagocytosis of late
apoptotic neutrophils by macrophages. Arthritis Rheum. (2004) 50:2667–74.
doi: 10.1002/art.20370
11. Mulay SR, Anders H-J. Crystallopathies. N Engl J Med. (2016) 374:2465–76.
doi: 10.1056/NEJMra1601611
12. Franklin BS, Mangan MS, Latz E. Crystal formation in
inflammation. Annu Rev Immunol. (2016) 34:173–202.
doi: 10.1146/annurev-immunol-041015-055539
13. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and
disease. Nature (2012) 481:278–86. doi: 10.1038/nature10759
14. Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN,
Vilaysane A, et al. Calcium oxalate crystals induce renal inflammation
by NLRP3-mediated IL-1β secretion. J Clin Invest. (2013) 123:236–46.
doi: 10.1172/JCI63679
15. Worcester EM, Coe FL. Clinical practice. Calcium kidney stones. N Engl J
Med. (2010) 363:954–63. doi: 10.1056/NEJMcp1001011
16. Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. (2012)
8:467–75. doi: 10.1038/nrneph.2012.113
17. Bhasin B. Primary and secondary hyperoxaluria: understanding the enigma.
World J Nephrol. (2015) 4:235. doi: 10.5527/wjn.v4.i2.235
18. Aggarwal KP, Narula S, Kakkar M, Tandon C. Nephrolithiasis: molecular
mechanism of renal stone formation and the critical role played by
modulators. Biomed Res Int. (2013) 2013:292953. doi: 10.1155/2013/292953
19. Baumann JM, Affolter B. From crystalluria to kidney stones, some
physicochemical aspects of calcium nephrolithiasis. World J Nephrol. (2014)
3:256–67. doi: 10.5527/wjn.v3.i4.256
20. Asselman M, Verhulst A, De Broe ME, Verkoelen CF. Calcium oxalate
crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing
injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol.
(2003) 14:3155–66. doi: 10.1097/01.ASN.0000099380.18995.F7
21. Wesson JA, Ward MD. Role of crystal surface adhesion in kidney
stone disease. Curr Opin Nephrol Hypertens. (2006) 15:386–93.
doi: 10.1097/01.mnh.0000232879.50716.6f
22. Sheng X, Jung T, Wesson JA, Ward MD. Adhesion at calcium oxalate crystal
surfaces and the effect of urinary constituents. Proc Natl Acad Sci USA. (2005)
102:267–72. doi: 10.1073/pnas.0406835101
23. Lieske JC, Swift H, Martin T, Patterson B, Toback FG. Renal epithelial
cells rapidly bind and internalize calcium oxalate monohydrate crystals.
Proc Natl Acad Sci USA. (1994) 91:6987–91. doi: 10.1073/pnas.91.1
5.6987
24. Sheng X, Ward MD, Wesson JA. Adhesion between molecules
and calcium oxalate crystals: critical interactions in kidney stone
formation. J Am Chem Soc. (2003) 125:2854–5. doi: 10.1021/ja02
9575h
25. Sheng X, Ward MD, Wesson JA. Crystal surface adhesion explains the
pathological activity of calcium oxalate hydrates in kidney stone formation.
J Am Soc Nephrol. (2005) 16:1904–8. doi: 10.1681/ASN.2005040400
26. Verhulst A, Asselman M, Persy VP, Schepers MSJ, Helbert MF, Verkoelen CF,
et al. Crystal retention capacity of cells in the human nephron: involvement
of CD44 and its ligands hyaluronic acid and osteopontin in the transition of
a crystal binding- into a nonadherent epithelium. J Am Soc Nephrol. (2003)
14:107–15. doi: 10.1097/01.ASN.0000038686.17715.42
27. Kumar V, Farell G, Deganello S, Lieske JC. Annexin II is present on renal
epithelial cells and binds calcium oxalate monohydrate crystals. J Am Soc
Nephrol. (2003) 14:289–97. doi: 10.1097/01.ASN.0000046030.24938.0A
28. Mulay SR, Eberhard JN, Desai J, Marschner JA, Kumar SVR, Weidenbusch
M, et al. Hyperoxaluria requires TNF receptors to initiate crystal
adhesion and kidney stone disease. J Am Soc Nephrol. (2016) 28:761–8.
doi: 10.1681/ASN.2016040486
29. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. (2013) 369:649–
58. doi: 10.1056/NEJMra1301564
30. Mulay SR, Anders H-J. Crystal nephropathies: mechanisms of
crystal-induced kidney injury. Nat Rev Nephrol. (2017) 13:226–40.
doi: 10.1038/nrneph.2017.10
31. Edyvane KA, Ryall RL, Marshall VR. The influence of serum and serum
proteins on calcium oxalate crystal growth and aggregation. Clin Chim Acta
(1986) 157:81–7. doi: 10.1016/0009-8981(86)90320-7
32. Ratkalkar VN, Kleinman JG. Mechanisms of stone formation. Clin Rev Bone
Miner Metab. (2011) 9:187–97. doi: 10.1007/s12018-011-9104-8
33. Steiger S, Grill JF, Ma Q, Bäuerle T, Jordan J, Smolle M, et al. Anti-
transforming growth factor β IgG elicits a dual effect on calcium oxalate
crystallization and progressive nephrocalcinosis-related chronic kidney
disease. Front Immunol. (2018) 9:619. doi: 10.3389/fimmu.2018.00619
34. Ryall RL, Chauvet MC, Grover PK. Intracrystalline proteins and urolithiasis:
a comparison of the protein content and ultrastructure of urinary calcium
oxalate monohydrate and dihydrate crystals. BJU Int. (2005) 96:654–63.
doi: 10.1111/j.1464-410X.2005.05701.x
35. Nancollas GH, Gardner GL. Kinetics of crystal growth of
calcium oxalate monohydrate. J Cryst Growth (1974) 21:267–76.
doi: 10.1016/0022-0248(74)90014-1
36. Liu J, Jiang H, Liu X-Y. How does bovine serum albumin prevent the
formation of kidney stone? A kinetics study. J Phys Chem B (2006) 110:9085–9.
doi: 10.1021/jp057403b
37. Inforzato A, Peri G, Doni A, Garlanda C, Mantovani A, Bastone A, et al.
Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-
tuning of the interaction with C1q and complement activation. Biochemistry
(2006) 45:11540–51. doi: 10.1021/bi0607453
38. Inforzato A, Reading PC, Barbati E, Bottazzi B, Garlanda C, Mantovani
A. The “sweet” side of a long pentraxin: how glycosylation affects PTX3
functions in innate immunity and inflammation. Front Immunol. (2012)
3:1–12. doi: 10.3389/fimmu.2012.00407
39. Inforzato A, Rivieccio V, Morreale AP, Bastone A, Salustri A, Scarchilli
L, et al. Structural characterization of PTX3 disulfide bond network and
its multimeric status in cumulus matrix organization. J Biol Chem. (2008)
283:10147–61. doi: 10.1074/jbc.M708535200
40. Inforzato A, Baldock C, Jowitt TA, Holmes DF, Lindstedt R, Marcellini M,
et al. The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric
Frontiers in Immunology | www.frontiersin.org 13 September 2018 | Volume 9 | Article 2173
Marschner et al. Novel Crystallization Inhibitor PTX3
octamer with two binding sites for FGF2. J Biol Chem. (2010) 285:17681–92.
doi: 10.1074/jbc.M109.085639
41. Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H,
et al. A subcellular map of the human proteome. Science (2017) 356.
doi: 10.1126/science.aal3321
42. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A,
et al. Proteomics. Tissue-based map of the human proteome. Science (2015)
347:1260419. doi: 10.1126/science.1260419
43. Mulay SR, Eberhard JN, Pfann V, Marschner JA, Darisipudi MN, Daniel
C, et al. Oxalate-induced chronic kidney disease with its uremic and
cardiovascular complications in C57BL/6 mice. Am J Physiol Physiol. (2016)
310:F785–95. doi: 10.1152/ajprenal.00488.2015
44. Grover PK, Moritz RL, Simpson RJ, Ryall RL. Inhibition of
growth and aggregation of calcium oxalate crystals in vitro–a co
mparison of four human proteins. Eur J Biochem. (1998) 253:637–44.
doi: 10.1046/j.1432-1327.1998.2530637.x
45. Nakagawa Y, Margolis H. Purification and characterization of a calcium
oxalate monohydrate crystal growth inhibitor from human kidney tissue
culture medium. J Biol Chem. (1981) 256:3936–3944.
46. Worcester M. Urinary calcium oxalate crystal growth inhibitors. J Am Soc
Nephrol. (1994) 5:S46–53.
47. Chen WC, Lin HS, Chen HY, Shih CH, Li CW. Effects of Tamm-Horsfall
protein and albumin on calcium oxalate crystallization and importance of
sialic acids.Mol Urol. (2001) 5:1–5. doi: 10.1089/109153601750124186
48. Viswanathan P, Rimer JD, Kolbach AM, Ward MD, Kleinman JG, Wesson
JA. Calcium oxalate monohydrate aggregation induced by aggregation
of desialylated Tamm-Horsfall protein. Urol Res. (2011) 39:269–82.
doi: 10.1007/s00240-010-0353-7
49. Alamani BG, Rimer JD. Molecular modifiers of kidney stones. Curr Opin
Nephrol Hypertens. (2017) 26:1. doi: 10.1097/MNH.0000000000000330
50. Gout E, Moriscot C, Doni A, Dumestre-Pérard C, Lacroix M, Pérard J,
et al. M-ficolin interacts with the long pentraxin PTX3: a novel case of
cross-talk between soluble pattern-recognition molecules. J Immunol. (2011)
186:5815–22. doi: 10.4049/jimmunol.1100180
51. Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, Zambelli V, et al.
Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat
Immunol. (2010) 11:328–34. doi: 10.1038/ni.1854
52. Lee TH, Lee GW, Ziff EB, Vilcek J. Isolation and characterization of eight
tumor necrosis factor-induced gene sequences from human fibroblasts. Mol
Cell Biol. (1990) 10:1982–8. doi: 10.1128/MCB.10.5.1982
53. Shiraki A, Kotooka N, Komoda H, Hirase T, Oyama J, Node K. Pentraxin-
3 regulates the inflammatory activity of macrophages. Biochem Biophys Rep.
(2016) 5:290–95. doi: 10.1016/j.bbrep.2016.01.009
54. Vasudevan V, Samson P, Smith AD, Okeke Z. The genetic framework
for development of nephrolithiasis. Asian J Urol. (2017) 4:18–26.
doi: 10.1016/j.ajur.2016.11.003
55. Rungroj N, Nettuwakul C, Sudtachat N, Praditsap O, Sawasdee N,
Sritippayawan S, et al. A whole genome SNP genotyping by DNA microarray
and candidate gene association study for kidney stone disease. BMC Med
Genet. (2014) 15:50. doi: 10.1186/1471-2350-15-50
56. Wolf MTF, Zalewski I, Martin FC, Ruf R, Müller D, Hennies HC, et al.
Mapping a new suggestive gene locus for autosomal dominant nephrolithiasis
to chromosome 9q33.2-q34.2 by total genome search for linkage.Nephrol Dial
Transplant. (2005) 20:909–14. doi: 10.1093/ndt/gfh754
57. Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M, et al. Genetic
PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med.
(2014) 370:421–32. doi: 10.1056/NEJMoa1211161
58. Hoover-Plow JL, Gong Y, Shchurin A, Busuttil SJ, Schneeman TA, Hart E.
Strain and model dependent differences in inflammatory cell recruitment in
mice. Inflamm Res. (2008) 57:457–63. doi: 10.1007/s00011-008-7062-5
59. Ishola DA, van der Giezen DM, Hahnel B, Goldschmeding R, Kriz W,
Koomans HA, et al. In mice, proteinuria and renal inflammatory responses
to albumin overload are strain-dependent. Nephrol Dial Transplant. (2006)
21:591–7. doi: 10.1093/ndt/gfi303
60. Reynolds J. Strain differences and the genetic basis of experimental
autoimmune anti-glomerular basement membrane glomerulonephritis.
Int J Exp Pathol. (2011) 92:211–7. doi: 10.1111/j.1365-2613.2011.00
763.x
61. RabeM, Schaefer F. Non-transgenicmousemodels of kidney disease.Nephron
(2016) 133:53–61. doi: 10.1159/000445171
62. Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, et al. Non-
redundant role of the long pentraxin PTX3 in anti-fungal innate immune
response. Nature (2002) 420:182–6. doi: 10.1038/nature01195
63. Knauf F, Asplin JR, Granja I, Schmidt IM, Moeckel GW, David RJ,
et al. NALP3-mediated inflammation is a principal cause of progressive
renal failure in oxalate nephropathy. Kidney Int. (2013) 84:895–901.
doi: 10.1038/ki.2013.207
64. Schreiber A, Shulhevich Y, Geraci S, Hesser J, Stsepankou D, Neudecker
S, et al. Transcutaneous measurement of renal function in conscious mice.
Am J Physiol Renal Physiol. (2012) 303:F783–8. doi: 10.1152/ajprenal.002
79.2012
65. Ma Q, Steiger S, Anders H-J. Sodium glucose transporter-2
inhibition has no renoprotective effects on non-diabetic chronic
kidney disease. Physiol Rep. (2017) 5:e13228. doi: 10.14814/phy2.
13228
66. Hagemann JH, Thomasova D, Mulay SR, Anders H-JJ. Nrf2 signalling
promotes ex vivo tubular epithelial cell survival and regeneration via murine
double minute (MDM)-2. Nephrol Dial Transplant. (2013) 28:2028–37.
doi: 10.1093/ndt/gft037
67. Terryn S, Jouret F, Vandenabeele F, Smolders I, Moreels M, Devuyst O,
et al. A primary culture of mouse proximal tubular cells, established
on collagen-coated membranes. AJP Ren Physiol. (2007) 293:F476–85.
doi: 10.1152/ajprenal.00363.2006
68. Thongboonkerd V, Semangoen T, Chutipongtanate S. Factors determining
types and morphologies of calcium oxalate crystals: molar concentrations,
buffering, pH, stirring and temperature. Clin Chim Acta (2006) 367:120–31.
doi: 10.1016/j.cca.2005.11.033
69. Rivieccio V, Esposito A, Bellofiore P, Palladino P, SassanoM, ColomboM, et al.
High-level expression and efficient purification of recombinant human long
pentraxin PTX3 in Chinese hamster ovary cells. Protein Expr Purif. (2007)
51:49–58. doi: 10.1016/j.pep.2006.07.009
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Marschner, Mulay, Steiger, Anguiano, Zhao, Boor, Rahimi,
Inforzato, Garlanda, Mantovani and Anders. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 14 September 2018 | Volume 9 | Article 2173
